These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 23844574)
1. Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. Shultz MD; Cheung AK; Kirby CA; Firestone B; Fan J; Chen CH; Chen Z; Chin DN; Dipietro L; Fazal A; Feng Y; Fortin PD; Gould T; Lagu B; Lei H; Lenoir F; Majumdar D; Ochala E; Palermo MG; Pham L; Pu M; Smith T; Stams T; Tomlinson RC; Touré BB; Visser M; Wang RM; Waters NJ; Shao W J Med Chem; 2013 Aug; 56(16):6495-511. PubMed ID: 23844574 [TBL] [Abstract][Full Text] [Related]
2. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors. Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969 [TBL] [Abstract][Full Text] [Related]
3. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors. Bregman H; Chakka N; Guzman-Perez A; Gunaydin H; Gu Y; Huang X; Berry V; Liu J; Teffera Y; Huang L; Egge B; Mullady EL; Schneider S; Andrews PS; Mishra A; Newcomb J; Serafino R; Strathdee CA; Turci SM; Wilson C; DiMauro EF J Med Chem; 2013 Jun; 56(11):4320-42. PubMed ID: 23701517 [TBL] [Abstract][Full Text] [Related]
4. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket. Bregman H; Gunaydin H; Gu Y; Schneider S; Wilson C; DiMauro EF; Huang X J Med Chem; 2013 Feb; 56(3):1341-5. PubMed ID: 23316926 [TBL] [Abstract][Full Text] [Related]
5. Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity. Buchstaller HP; Anlauf U; Dorsch D; Kuhn D; Lehmann M; Leuthner B; Musil D; Radtki D; Ritzert C; Rohdich F; Schneider R; Esdar C J Med Chem; 2019 Sep; 62(17):7897-7909. PubMed ID: 31381853 [TBL] [Abstract][Full Text] [Related]
6. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443 [TBL] [Abstract][Full Text] [Related]
7. Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases. Shultz MD; Majumdar D; Chin DN; Fortin PD; Feng Y; Gould T; Kirby CA; Stams T; Waters NJ; Shao W J Med Chem; 2013 Sep; 56(17):7049-59. PubMed ID: 23879431 [TBL] [Abstract][Full Text] [Related]
8. para-Substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors. Haikarainen T; Koivunen J; Narwal M; Venkannagari H; Obaji E; Joensuu P; Pihlajaniemi T; Lehtiö L ChemMedChem; 2013 Dec; 8(12):1978-85. PubMed ID: 24130191 [TBL] [Abstract][Full Text] [Related]
9. Screening and structural analysis of flavones inhibiting tankyrases. Narwal M; Haikarainen T; Fallarero A; Vuorela PM; Lehtiö L J Med Chem; 2013 May; 56(9):3507-17. PubMed ID: 23574272 [TBL] [Abstract][Full Text] [Related]
10. Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor. Voronkov A; Holsworth DD; Waaler J; Wilson SR; Ekblad B; Perdreau-Dahl H; Dinh H; Drewes G; Hopf C; Morth JP; Krauss S J Med Chem; 2013 Apr; 56(7):3012-23. PubMed ID: 23473363 [TBL] [Abstract][Full Text] [Related]
11. Iminopyrimidinones: a novel pharmacophore for the development of orally active renin inhibitors. McKittrick BA; Caldwell JP; Bara T; Boykow G; Chintala M; Clader J; Czarniecki M; Courneya B; Duffy R; Fleming L; Giessert R; Greenlee WJ; Heap C; Hong L; Huang Y; Iserloh U; Josien H; Khan T; Korfmacher W; Liang X; Mazzola R; Mitra S; Moore K; Orth P; Rajagopalan M; Roy S; Sakwa S; Strickland C; Vaccaro H; Voigt J; Wang H; Wong J; Zhang R; Zych A Bioorg Med Chem Lett; 2015 Apr; 25(7):1592-6. PubMed ID: 25728416 [TBL] [Abstract][Full Text] [Related]
12. [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. Shultz MD; Kirby CA; Stams T; Chin DN; Blank J; Charlat O; Cheng H; Cheung A; Cong F; Feng Y; Fortin PD; Hood T; Tyagi V; Xu M; Zhang B; Shao W J Med Chem; 2012 Feb; 55(3):1127-36. PubMed ID: 22260203 [TBL] [Abstract][Full Text] [Related]
13. Novel binding mode of a potent and selective tankyrase inhibitor. Gunaydin H; Gu Y; Huang X PLoS One; 2012; 7(3):e33740. PubMed ID: 22438990 [TBL] [Abstract][Full Text] [Related]
14. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors. Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427 [TBL] [Abstract][Full Text] [Related]
15. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor. Karlberg T; Markova N; Johansson I; Hammarström M; Schütz P; Weigelt J; Schüler H J Med Chem; 2010 Jul; 53(14):5352-5. PubMed ID: 20565110 [TBL] [Abstract][Full Text] [Related]
16. Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach. Anumala UR; Waaler J; Nkizinkiko Y; Ignatev A; Lazarow K; Lindemann P; Olsen PA; Murthy S; Obaji E; Majouga AG; Leonov S; von Kries JP; Lehtiö L; Krauss S; Nazaré M J Med Chem; 2017 Dec; 60(24):10013-10025. PubMed ID: 29155568 [TBL] [Abstract][Full Text] [Related]
17. Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066). Watterson SH; Langevine CM; Van Kirk K; Kempson J; Guo J; Spergel SH; Das J; Moquin RV; Dyckman AJ; Nirschl D; Gregor K; Pattoli MA; Yang X; McIntyre KW; Yang G; Galella MA; Booth-Lute H; Chen L; Yang Z; Wang-Iverson D; McKinnon M; Dodd JH; Barrish JC; Burke JR; Pitts WJ Bioorg Med Chem Lett; 2011 Dec; 21(23):7006-12. PubMed ID: 22018461 [TBL] [Abstract][Full Text] [Related]
18. Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines. Thomson DW; Wagner AJ; Bantscheff M; Benson RE; Dittus L; Duempelfeld B; Drewes G; Krause J; Moore JT; Mueller K; Poeckel D; Rau C; Salzer E; Shewchuk L; Hopf C; Emery JG; Muelbaier M J Med Chem; 2017 Jul; 60(13):5455-5471. PubMed ID: 28591512 [TBL] [Abstract][Full Text] [Related]
19. Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer. Shirai F; Mizutani A; Yashiroda Y; Tsumura T; Kano Y; Muramatsu Y; Chikada T; Yuki H; Niwa H; Sato S; Washizuka K; Koda Y; Mazaki Y; Jang MK; Yoshida H; Nagamori A; Okue M; Watanabe T; Kitamura K; Shitara E; Honma T; Umehara T; Shirouzu M; Fukami T; Seimiya H; Yoshida M; Koyama H J Med Chem; 2020 Apr; 63(8):4183-4204. PubMed ID: 32202790 [TBL] [Abstract][Full Text] [Related]
20. Optimization of a Screening Hit toward M2912, an Oral Tankyrase Inhibitor with Antitumor Activity in Colorectal Cancer Models. Buchstaller HP; Anlauf U; Dorsch D; Kögler S; Kuhn D; Lehmann M; Leuthner B; Lodholz S; Musil D; Radtki D; Rettig C; Ritzert C; Rohdich F; Schneider R; Wegener A; Weigt S; Wilkinson K; Esdar C J Med Chem; 2021 Jul; 64(14):10371-10392. PubMed ID: 34255518 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]